Continuous dopaminergic stimulation
|
|
- Anthony Fisher
- 6 years ago
- Views:
Transcription
1 Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS RTG 1
2 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa Dyskinesia Dyskinesia Dyskinesia on on on off off off Antonini. Parkinsonism Relat Disord 2007;13(Suppl 3):S GPSRC CNS RTG 2
3 Evidence for effectiveness of continuous dopaminergic stimulation in early disease Early continuous dopaminergic stimulation can delay or prevent motor fluctuations and dyskinesia in patients with early PD Proven? GPSRC CNS RTG 3
4 COMT-inhibitors improve levodopa pharmacokinetics but not sufficiently to stabilize plasma levels Levodopa Concentration n (nmol/ml) With Entacapone Without Entacapone Levodopa Administration Time of day Levodopa ncentration (µg/l) con CURS SΣ Fig 2. Concentration-time profile (top) and effect-time profile (bottom) of levodopa over 4 consecutive dosage intervals before and during coadministration of tolcapone 100mg 3 times daily for 7 days. Values are means ± SD. Nutt. Neurology 2000;55:S33 7. *Baas et al. Clin Pharmacokinet 2001;40: COMT, catecholamine O-methyl transferase To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 4
5 Reduced dyskinesias with ropinirole in a naturalistic 10-year follow-up of early PD patients who had initially received ropinirole or L-dopa Development of dyskinesias Development of dyskinesias Median time to develop dyskinesias Patien nts (%) p = % 71% Time (years) p = Ropirinole Levodopa Ropirinole Levodopa Hauser et al. Mov Disord 2007;22: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 5
6 Comparison of the agonist pramipexole versus levodopa on motor complications of Parkinson's disease (CALM-PD): 6-year prospective evaluation Endpoint Initial Pramipexole Initial Levodopa p Mean Schwab and England ADL Scale score (SD) 79.9 (16.2) (14.6) Dopaminergic motor complications (%) Mean Epworth Sleepiness Scale score (SD) 11.3 (5.8) 8.6 (4.7) <0.001 Mean change from baseline in UPDRS score (SD) 2.4 (17.4) 0.5 (17.1) 0.11 Parkinson Study Group CALM Cohort Investigators. Arch Neurol 2009;66: To view notes, click pause and then click on notes tab GPSRC CNS RTG 6
7 Potential for continuous dopaminergic stimulation in early Parkinson s s disease: clinical evidence Dopamine agonists vs levodopa: 29 studies, 5247 patients Adapted from: Stowe RL, et al. Cochrane Database of Systematic Reviews 2008;Issue 2. To view notes, click pause and then click on notes tab GPSRC CNS RTG 7
8 Evidence for effectiveness of continuous dopaminergic stimulation in advanced disease Continuous dopaminergic stimulation can reverse motor fluctuations and dyskinesia in patients with advanced PD Proven? GPSRC CNS RTG 8
9 Continuous dopaminergic stimulation widens therapeutic window in advanced PD on Infusion begins GPSRC CNS RTG 9
10 Rotigotine patch reduced off time in advanced PD LeWitt et al. Neurology 2007;68: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 10
11 Rotigotine patch in advanced PD Study Dose Mean daily dose Levodopa Off (h) baseline Off (h) change from baseline Responders % LeWitt et al. ROT ROT Placebo Poewe et al. ROT PPX Placebo A significant amount of off time still remained after the introduction of rotigotine/pramipexole Placebo responder rate was very high LeWitt et al. Neurology 2007;68:1262 7; Poewe et al. Lancet Neurol 2007;6: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 11
12 Rotigotine patch in advanced PD Study Dose No off periods On (h) without troublesome dyskinesia UPRDS ADL change UPDRS motor change LeWitt et al. ROT ROT Placebo Poewe et al. ROT PPX Placebo Quality of life (ADL) improved much less than motor function ADL, activities of daily living; UPRDS, Unified Parkinson s Disease Rating Scale LeWitt et al. Neurology 2007;68:1262 7; Poewe et al. Lancet Neurol 2007;6: GPSRC CNS RTG 12
13 Subcutaneous apomorphine infusion The speaker has requested that t this slide is not shown for copyright reasons GPSRC CNS RTG 13
14 Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa-induced interdose dyskinesias in PD o off hours (% of wak king hours ) OFF HOURS e) UPDRS score DYSKINESIA p < 0.01 p < 0.01 *** baseline 1 year Dy yskinesia disablity (U *** baseline 1 year Apomorphine monotherapy (waking day) Colzi et al. J Neurol Neurosurg Psychiatry 1998;64: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 14
15 Changes in 15 patients after apomorphine infusion for 1 year Significant reduction in off time but little effect on dyskinesia Levodopa dose equivalents De Gaspari et al. J Neurol Neurosurg Psychiatry 2006;77: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 15
16 Continuous apomorphine reduced dyskinesia severity on acute challenge Baseline 6-month Change Levodopa challenge AIM dyskinesia scale ± ± % Goetz dyskinesia scale 2.2 ± ± % Apomorphine challenge AIM dyskinesia scale 9.7 ± ± % Goetz dyskinesia scale 2.2 ± ± % AIM, abnormal involuntary movement Katzenschlager et al. Mov Disord 2005;20: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 16
17 Long-term lisuride infusion reduces Off hours and dyskinesia compared to standard oral levodopa therapy Stocchi et al Brain 2002;125: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 17
18 Widening the levodopa therapeutic window using continuous lisuride infusion for 3 months Baronti et al. Ann Neurol 1992;32: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 18
19 Intrajejunal levodopa titration Patient 2 (P.T.) Oral medical treatment Baseline Day 3 - Naso-duodenal tube, infusion begins 1\2 levodopa oral 125 mg h h Time of day (h) Time of day (h) Madopar mg: 3/4cp x 3 + 1/2cp x 3 Levomet:1 puff x 4 Apofin stylo: 5 mg x 3 s.c. Mirapexin 0.7 mg: 1/2cp x Daily dose Continuous dose rate (ml/h) Dose extra (ml) Other treatment Week months Time of day (h) Daily dose Continuous dose rate (ml/h) Dose extra (ml) Time of day (h) Daily dose Continuous dose rate (ml/h) Dose extra (ml) Benefit occurred after withdrawal of all oral medications, personal data GPSRC CNS RTG 19
20 Intrajejunal infusion is possible through a gastrostomy and levodopa is delivered by a pump The speaker has requested that t this slide is not shown for copyright reasons GPSRC CNS RTG 20
21 Duodenal infusion makes levodopa bioavailability and plasma levels more predictable compared with oral tablets 47% decrease in plasma levodopa variability (p = 0.01) Kurth et al. Neurology 1993;43: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 21
22 Daily dose of levodopa and equivalents administered did not change Me ean (SD) dai ily dose of levodopa (m mg/kg) ± ± ±325 Baseline Month 6 * Month 12 * Min, Max n 825, , , * Includes morning bolus and one extra afternoon dose Antonini et al. Mov Disord 2007;22: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 22
23 Total daily duration of off periods was reduced by over 80% ) Mean (SD) total daily durat tion off period ds (minutes of ± ± ± 16.0 Baseline Month 6 ** Month 12 ** Min, Max 100, , 60 15, 60 n **p < 0.01 vs baseline Antonini et al. Mov Disord 2007;22: GPSRC CNS RTG 23
24 Total daily duration of moderate-severe dyskinesia was reduced by over 80% Mean (SD) total daily durat ion of moderate to severe dyskinesia (minutes) ± ± ± Baseline Month 6 ** Month 12 ** Min, Max 60, , 90 20, 80 n **p < 0.01 vs baseline Antonini et al. Mov Disord 2007;22: GPSRC CNS RTG 24
25 Patient video With permission from Dr Riboldazzi, Varese, Italy With permission from Dr Riboldazzi, Varese, Italy GPSRC CNS RTG 25
26 Benefit on quality of life (PDQ 39) after 1 year *p < 0.05 Baseline Year 1 *p < 0.05 **p < 0.01 **p < 0.01 Score (as sub-item of PDQ-39) PDQ, Parkinson s Disease Questionnaire Antonini et al. Mov Disord 2007;22: GPSRC CNS RTG 26
27 Effect size of duodenal levodopa on non-motor symptoms in health st tatus Change -0.4 Cognition Attention Mood Gastro- intestinali CVS Sleep Urinary Sex -1.4 Miscellaneous < 0.2 = negligible; = small; = moderate; > 0.8 = large (Kazis et al. Med Care 1989;27:S178 89) CVS: cardiovascular symptoms Honig et al. Mov Disord 2009;24: To view abstract, click pause then click Abstracts link above GPSRC CNS RTG 27
28 Summary Motor complications (wearing-off and dyskinesia) i are frequently observed with disease progression and chronic pulsatile levodopa treatment Progressive denervation and fluctuations in plasma levodopa levels are likely to contribute to the development of motor complications Continuous dopaminergic stimulation can delay complications in early PD and reverse them in advanced patients with benefit extending to quality of life and non-motor symptoms GPSRC CNS RTG 28
29 PD treatment algorithm Add MAO-B inhibitor (i.e. rasagiline 1 mg/day) Raise dopamine agonist dose if tolerated Add amantadine up to 100 mg three times daily Untreated Insufficient motor control Wearing-off Dyskinesia Start with non- ergot agonist and raise to average effective dose Add levodopa three times daily Try not exceed mg/day Increase frequency of levodopa administration Use entacapone Adjust levodopa dose Consider tolcapone Consider more invasive therapies (DBS apomorphine or levodopa duodenal infusion) DBS, deep brain stimulation; MAO-B, mono-amine oxidase B Antonini & Barone. Neurol Sci 2008;29:S GPSRC CNS RTG 29
30 Copyright statements Slide , reproduced with permission from John Wiley & Son, Inc, and 2001, reproduced with permission from Wolters Kluwer Health Slide , reproduced d with permission i from Wolters Kluwer Health Slide , reproduced with permission from the BMJ Publishing Group Slide , reproduced with permission from John Wiley & Sons, Inc Slide 18 Slide , reproduced with permission from Oxford University Press 1992, reproduced with permission from John Wiley & Sons, Inc GPSRC CNS RTG 30
31 Copyright statements Slide 22 Slide 23 Slide 24 Slide 25 Slide 27 Slide 28 Slide , reproduced with permission from Wolters Kluwer Health 2007, reproduced with permission from John Wiley & Sons, Inc 2007, reproduced with permission from John Wiley & Sons, Inc 2007, reproduced with permission from John Wiley & Sons, Inc 2007, reproduced with permission from John Wiley & Sons, Inc 2009, reproduced with permission from John Wiley & Sons, Inc 2008, reproduced with permission from Springer GPSRC CNS RTG 31
Treatment of sleep disorders in
Treatment of sleep disorders in Parkinson s s disease (PD) K. Ray Chaudhuri London, UK GPSRC CNS 176 0709 RTG 1 Managing insomnia in PD Onset/initiation Adjustment of anti-pd treatment Sleep hygiene Hypnotics
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS INFUSION THERAPIES IN PARKINSON S DISEASE Apomorphine, T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR FLUCTUATIONS
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationSafinamide: un farmaco innovativo con un duplice meccanismo d azione
Safinamide: un farmaco innovativo con un duplice meccanismo d azione AINAT Sardegna Cagliari, 26 novembre 2016 Carlo Cattaneo Corporate Medical Advisor CNS & Rare Diseases Reichmann H. et al., European
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationPDL Class: Parkinson s Drugs
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review: September 2013 Date of Last Review:
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationKEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?
KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationReport on New Patented Drugs Azilect
Report on New Patented Drugs Azilect Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More informationAbbreviated Class Update: Parkinson s Drugs. Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. MAO- B** Inhibitors
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Class Update: Parkinson s Drugs Month/Year of Review: November 2013 End of literature
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationRotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research
Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder
More informationThe impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson s disease: an observational study
Pellicano et al. European Journal of Medical Research 2013, 18:60 EUROPEAN JOURNAL OF MEDICAL RESEARCH RESEARCH Open Access The impact of extended release dopamine agonists on prescribing patterns for
More informationAPOMORPHINE OLD DRUG ; NEW LIFE?
APOMORPHINE OLD DRUG ; NEW LIFE? Dr Susan H Fox MRCP (UK), PhD Professor Neurology, University of Toronto Movement Disorders Clinic, Toronto Western Hospital CNSF, Halifax June 25 th 2018 DISCLOSURES Nature
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationRotigotine provided sustained efficacy and tolerability in long term studies of early and late stage idiopathic Parkinson s disease
New data presented at the American Academy of Neurology meeting showed that Neupro (rotigotine transdermal system) improved both motor and non-motor symptoms of Parkinson s disease Analysis of RECOVER
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationEvidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease: 2001 to 2004
Movement Disorders Vol. 20, No. 5, 2005, pp. 523 539 2005 Movement Disorder Society Research Review Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease:
More informationFinal Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK
Final Appraisal Report Ropinirole prolonged-release (Requip XL ) for the treatment of idiopathic Parkinson s disease GlaxoSmithKline UK Advice No: 1409 August 2009 Recommendation of AWMSG Ropinirole prolonged-release
More informationOptimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationEvidence compendium. Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease
Evidence compendium Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease CONTENTS Introduction... 4 Index of study summaries... 6 Parkinson s disease
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationDuodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Articles CME VIDEO Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease D. Nyholm, MD, PhD; A.I.M. Nilsson Remahl, MD, PhD; N. Dizdar, MD, PhD; R. Constantinescu, MD;
More informationKeywords: deep brain stimulation; subthalamic nucleus, subjective visual vertical, adverse reaction
Re: Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation Norbert Kovacs 1*, Jozsef Janszky 1, Ferenc
More informationRotigotine transdermal patch in the management of Parkinson s disease (PD) and its night-time use for PD-related sleep disorders
Rotigotine transdermal patch in the management of Parkinson s disease (PD) and its night-time use for PD-related sleep disorders Angelo Antonini, MD, PhD a,b,c Laura Bernardi, MD a Daniela Calandrella,
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationNEW DEVELOPMENTS FOR PARKINSON S THERAPY WITH COMT INHIBITORS
NEW DEVELOPMENTS FOR PARKINSON S THERAPY WITH COMT INHIBITORS This symposium took place on 22 nd September 2016 as a part of the 89 th Deutsche Gesellschaft für Neurologie (DGN) Congress in Mannheim, Germany
More informationEarly Treatment Options When to start, what with, and why?
September 2014 Early Treatment Options When to start, what with, and why? Dr Doug MacMahon FRCP (Lond. & Edin) dgmacmahon@hotmail.com Disclosure Dr MacMahon has received honoraria, fees for advisory boards,
More informationCONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON S DISEASE: A FOLLOW-UP OF TWO YEARS.
Arch. Gerontol. Geriatr. Suppl. 9 (2004) 291 296 0167-4943/$ see front matter # 2004 Elsevier Ireland Ltd. All rights reserved CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS
More informationContinuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report
Acta Biomed 2017; Vol. 88, N. 2: 190-195 DOI: 10.23750/abm.v88i2.5038 Mattioli 1885 Case report Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationSummary of Patient < 3y at Visit 11 (90 months)
Summary of Patient < 3y at 11 (90 months) Clinician Scoring Page Direct online data entry available? Medication 378 Yes BPW 382 Yes Diagnostic Features 383 Yes UPDRS Clinician 388 Yes CISI-PD 397 Yes MoCA
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationKen Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe and Yasuo Iwasaki. Abstract
ORIGINAL ARTICLE Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson s Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists Ken Ikeda,
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationORIGINAL CONTRIBUTION. Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease
ORIGINAL CONTRIBUTION Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease A Clinical and Pharmacokinetic Study Fabrizio Stocchi, MD, PhD; Laura Vacca, MD, PhD;
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationPatients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment
For the attention of accredited medical writers only Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment Data presented at the 7
More informationParkinson s Disease medications
Parkinson s Disease medications In correlation to the Unified Parkinson s disease rating scale Ayaan Mohamed Degree Thesis in Pharmacy 15 ECTS Bachelor s Level Report passed: Spring 2017 Supervisor: Miles
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationThe Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications
The Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications Carlos Singer, MD* Spiridon Papapetropoulos, MD, PhD* Gadith Uzcategui, BA Lydia Vela, MD * Department of Neurology, University
More informationGuidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth
Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name
More informationOverview of Parkinson s disease Research at University of Colorado
Overview of Parkinson s disease Research at University of Colorado Brian D. Berman, MD, MS May 12, 2018 University of Colorado Movement Disorders Center Terminology Basic science pure/fundamental scientific
More informationSwitching from pergolide to pramipexole in patients with Parkinson s disease
J Neural Transm (2001) Switching 108: 63 70 from pergolide to pramipexole in PD 63 Switching from pergolide to pramipexole in patients with Parkinson s disease P. A. Hanna 1,2, L. Ratkos 2, W. G. Ondo
More informationAppendix 2: Admissions checklists for people with Parkinson s
Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,
More informationREFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Sales for Parkinson s Disease in the US The Parkinson s disease market in the
More informationWhat is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More information14 : 4. D Nagaraja, Pramod Kumar Pal, N Karthik, Bangalore. Abstract:
14 : 4 Management of Parkinson s disease: What is new? Abstract: Parkinson s disease (PD) is a progressive disorder, which however can be treated satisfactorily with a judicial combination of medical and
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationAnand R, 1 Borgohain R, 2 Stocchi F, 3 Giuliani R, 4 Rice P, 5 Forrest E, 4 Lucini V, 4 for the Study 016/018 Investigators IL, USA
First 2-year, placebo-controlled study in Parkinson s disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia Anand R, 1 Borgohain R, 2 Stocchi F,
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationREFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Parkinson s Disease in Japan Market The Parkinson
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationRECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease
For the attention of Accredited Medical Writers Only RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease Post hoc analyses of RECOVER study suggested
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationNeupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease
For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationWhat is Augmentation? How to diagnose? What to do?
What is Augmentation? How to diagnose? What to do? Diego Garcia-Borreguero Madrid, SPAIN Dopaminergics do work: The case of L-dopa 100 80.005.031.002.025 ns ns p-values PLM/h 60 40 Placebo L-Dopa 20 0
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More information